NCT04504942Phase 2Completed

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2021-11-07Actual

Enrollment · participants16Actual

Source updated2026-01-23Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-11-18 · 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: Number, ~~frequency~~, and ~~severity~~ of ~~adverse events~~ (~~AEs~~) ~~Measure: Incidence of abnormal laboratory tests results~~ Measure: Changes in Eastern Cooperative Oncology Group (ECOG) ~~performance~~ ~~status~~ ~~from~~ ~~baseline~~ to ~~subsequent~~ ~~scheduled~~ ~~visits~~

+ After

Measure: Number of Participants With Adverse Events (AEs), and Serious Adverse Events (SAEs). Measure: Changes in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to Subsequent Scheduled Visits

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~30 participants (planned)~~

+ After

16 participants (actual)

Recruitment status changed

− Before

~~Active not recruiting~~

+ After

Completed

Check registry source

Study details

Conditions studied

Solid Tumor, Adult

Treatments or interventions studied

LeronlimabDrugAlso known as Standard-of-care chemotherapy or radiotherapy

Primary outcomes · main study measures

Read the study measures

measure: Number of Participants With Adverse Events (AEs), and Serious Adverse Events (SAEs).; description: Adverse events were elicited through direct questioning and subject reports. Any abnormalities in visit evaluations, physical examination findings or laboratory results that the investigator believed were clinically significant to the research subject were reported as adverse events.; timeFrame: From the time of first treatment (T1) until the last study visits completion (up to approximately 16 months); measure: Changes in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to Subsequent Scheduled Visits; description: The ECOG was utilized to assess the ability of patients to tolerate treatment. The ECOG is a 5-point scale, where a higher score indicates a greater lack of tolerance of the treatment. Response choices included: 0 = Asymptomatic; Fully active, able to carry on all pre-disease performance without restriction, 1 = Symptomatic but completely ambulatory; Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work, 2 = Symptomatic, \<50% in bed during the day; Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours, 3 = Symptomatic, \>50% in bed during the day; Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours, 4 = Bedbound; Completely disabled; cannot carry on any selfcare; totally confined to bed or chair, 5 = Dead.; timeFrame: From the time of first treatment (T1) until the last study visits completion (up to approximately 16 months)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history